Catalyst Pharmaceuticals (CPRX) Cash & Equivalents (2010 - 2026)

Catalyst Pharmaceuticals (CPRX) has 17 years of Cash & Equivalents data on file, last reported at $755.9 million in Q1 2026.

• Quarterly Cash & Equivalents rose 30.17% year-over-year to $755.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $755.9 million (up 30.17% YoY) and the FY2025 annual result came in at $709.2 million, up 37.02% from the prior year.
• Cash & Equivalents climbed to $755.9 million in Q1 2026, from $709.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $755.9 million in Q1 2026 to a low of $121.0 million in Q3 2023.
• A 5-year average of $386.1 million and a median of $310.4 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents sank 53.87% — and 2024, when it jumped 276.03%.
• Tracing CPRX's Cash & Equivalents over 5 years: stood at $298.4 million in 2022, then slumped by 53.87% to $137.6 million in 2023, then jumped by 276.03% to $517.6 million in 2024, then surged by 37.02% to $709.2 million in 2025, then increased by 6.58% to $755.9 million in 2026.
• The last three Cash & Equivalents figures came in at $755.9 million (Q1 2026), $709.2 million (Q4 2025), and $689.9 million (Q3 2025), per Business Quant data.